1. Moleculin Biotech presented at the Virtual Investor Conference. 2. The company emphasizes attention for investment in 2025. 3. Annamycin targets hard-to-treat cancers, undergoing Phase 3 trials. 4. Successful Phase 1B/2 study de-risks Annamycin's approval path. 5. Moleculin is also developing other cancer treatment candidates.
Moleculin's development of Annamycin and promising trial data can attract investors, similar to previous biotech successes like Gilead's approval of antiviral treatments, positively influencing pricing.
The article highlights key advancements in Moleculin’s drug pipeline, essential for driving investor interest and market performance.
Positive feedback and trial progress can lead to immediate investor interest and stock price movement, as seen in companies making significant development announcements.
HOUSTON, March 11, 2025 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company") a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced it participated in the Virtual Investor "Top 5 for '25" On-Demand Conference.
As part of the event, Walter Klemp, Chairman and Chief Executive Officer of Moleculin, presented the top five reasons of why he believes the investment community and industry colleagues should pay attention to Moleculin in 2025.
The on-demand video webcast is now accessible for viewing here and on the Events page in the Investors section of the Company's website (moleculin.com).
Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and viruses. The Company's lead program, Annamycin, is a next-generation anthracycline designed to avoid multidrug resistance mechanisms and to eliminate the cardiotoxicity common with currently prescribed anthracyclines. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.
The Company is initiating the MIRACLE (Moleculin R/R AML AnnAraC Clinical Evaluation) Trial (MB-108), a pivotal, adaptive design Phase 3 trial evaluating Annamycin in combination with cytarabine, together referred to as AnnAraC, for the treatment of relapsed or refractory acute myeloid leukemia. Following a successful Phase 1B/2 study (MB-106), with input from the FDA, the Company believes it has substantially de-risked the development pathway towards a potential approval for Annamycin for the treatment of AML. This study is subject to appropriate future filings with potential additional feedback from the FDA and their foreign equivalents.
Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers. Moleculin is also engaged in the development of a portfolio of antimetabolites, including WP1122 for the potential treatment of pathogenic viruses, as well as certain cancer indications. For more information about the Company, please visit www.moleculin.com and connect on X, LinkedIn and Facebook.
Investor Contact: JTC Team, LLC
Jenene Thomas
(908) 824-0775
info@moleculin.com
SOURCE Moleculin Biotech, Inc.